All news

At $57.10 a share, Royalty Pharma (RPRX) EVP Marshall Urist sells 4,126 shares.

Alpha Vantage · Stock Titan · · AI-summarised by FinFlash

Marshall Urist, EVP of Research & Investments at Royalty Pharma plc, sold 4,126 Class A Ordinary Shares at $57.10 per share on October 5, 2026. This transaction was conducted under a Rule 10b5-1 plan adopted in June 2026, resulting in a direct holding of 0 shares post-sale, though he indirectly holds 19,020 shares via an IRA.

Read original source

RPRX company analysis

Understand the context

Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.